NASHVILLE, Tenn., November 1, 2022 /PRNewswire/ — Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), the largest public biopharmaceutical company founded and headquartered in Tennesseetoday announced the move of its headquarters to broadwest campuses in the Vanderbilt/West End Corridor of Nashville. The company is focused on its mission to advance patient care through the delivery of high quality medicines.

Located at 1600 West End Ave., Broadwest is a 1.2 million square foot mixed-use urban development and business park – with office, high-end condominiums, luxury hotel and retail space. It includes a 21-story office tower with over 500,000 square feet of corporate space. In addition, Broadwest has outdoor amenity space for tenants to which cumberland has access.

from Cumberland The move allows the company to accommodate recent growth and better serve its international customer and partner base. Following the expansion, from Cumberland the organization will grow to over 100 people, the majority of them employed within the company Nashville Headquarter.

“As the national center of the healthcare industry, Nashville has proven to be an ideal location for us to build our healthcare company,” said AJ Kazimi, CEO of Cumberland Pharmaceuticals. “With a growing portfolio of FDA-approved brands and an extensive pipeline of new drugs for the future, we are poised for significant milestones in the years to come. I am confident that this new, well-located, state-of-the-art headquarters will play an important role in our future success.”

cumberland maintained a presence in Nashville since its founding in 1999. Its former headquarters were located in the 2525 West End building across from Centennial Park. As the company works in partnership with prestigious academic institutions, its new headquarters retains cumberland close to national fame Vanderbilt University Medical Center to enable their continued collaboration.

“Our state’s central location, skilled workforce and strong business climate allow Tennessee businesses to grow and expand,” said Tennessee Department of Economic and Community Development Commissioner Stuart McWhorter. “I thank Cumberland Pharmaceuticals for creating new opportunities in Middle Tennessee, where it is leading the growth of the life science/biopharmaceutical industry. We believe Nashville will continue to be the ideal place for from Cumberland international headquarters.”

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on providing high quality prescription brands designed to improve patient care. The company develops, acquires and markets products for the hospital acute care, gastroenterology, rheumatology and oncology market segments. The company’s portfolio includes eight FDA-approved brands.

The company also has a series of ongoing Phase II clinical programs evaluating its product candidate ifetroban in patients with cardiomyopathy associated with Duchenne muscular dystrophy, systemic sclerosis and aspirin-exacerbated respiratory disease. More information can be found on the company’s website at

SOURCECumberland Pharmaceuticals Inc.


Comments are closed.